1[2]Sobotova D,Zharfbin A,Svojanovsky J,et al.Hypertension in hemodialyzed uremic patients[J].Vnitr Lek,1999,45(11):641-644.
2[3]London G M,Parfrey P S.Cardiac disease in chronic uremia:pathogenesis[J].Adv Ren Replace Ther,1997,4(3):194-211.
3[4]Meeus F,Kourilsky O,Guerin A P,et al.Pathophysiology of cardiovascular disease in hemodialysis patients[J].Kidney Int Suppl,2000,76:S140-147.
4[5]Stenvinkel P.Inflammatory and atherosclerotic interactions in the depleteduremic patient[J].Blood Purif,2001,19(1):53-61.
5[6]Ronco C,Bellom R.Continuous renal replacement therapy:Evolution intechnology and current nomenclature [J].Kidney Int,1998,53(Suppl166):160-165.
6[7]Van Bommel E,Bouvy N D,So K L,et al.Acute dialytic support for thecritically ill:Intermittent HD versus continuous arteriovenous hemodiafiltration[J].Am J Nephrol,1995,15(3):192.
7Bellomo R,Ronco C.Indications and criteria for initiating renal replacement therapy in the intensive care unit[J].Kidney Int,1998,53(Suppl 66):S106-2S109.
8Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the Use of innovative therapies in sepsis.The ACCP/SCCM Consensus College of Chest Physicians/Society of Critical Care Medicine[J].Chest,1992,101(6):1644-1655.
9Singer M,Suntis VD,Vitale D,et al.Multiorgan failure is an adaptive,endocrine-mediated,metabolic response to overwhelming systemic inflammation[J].Lancet,2004,364(8):545-548.
10Balk RA,Cerra FB,Dellinger RP,et al.Definitions of sepsis and organ failure and guidelines for the user of innovative therapies in sepsis[J].Crit Care Med,1992,20(6):864-874.
